TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/05/2026
Voltar para busca
Dado oficial do USPTO
BAUSCH HEALTH
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
BAUSCH HEALTH
ST13
US500000087884008Classe
5, 41, 44
Pedido
87884008
Registro
6974682
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
81
Atualização mais recente
16/05/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 41, 44
Data de depósito
19/04/2018
Data de registro
07/02/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/02/2023
Última transação
16/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
12/03/2014
Primeiro uso no comércio
12/03/2014
Código do desenho
4
Tipo de titular
03
Localização do titular
Rochester, NY, US
Examinador
DELGIZZI, RONALD ERNEST
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Bausch & Lomb Incorporated
Representantes
Robert J. Gorman Bausch + Lomb
Classificação técnica
Classes Nice
Classe 5Classe 41Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
cardiovascular system; pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonaryhepatologicalrespiratoryneurologicalrespiratoryneurologicalhormonalpsychiatric and immune system related diseases and disorders; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparationsimmunomodulators; anticholinesterase preparation for the preventiontreatment and alleviation of neurological disorders; Vaginally administered metronidazole gel for use in the treatment of vaginal disorders; intravenous preparations for the treatment of hyperammonemia of all origins; Skin patch for delivering nitroglycerin to a medical patient; anticonvulsants; pharmaceutical preparations and substances for the preventiontreatment and alleviation of stress; pharmaceutical preparations and substances for the preventiontreatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the preventiontreatment and alleviation of hypertension; pharmaceutical preparations and substances for the preventiontreatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the preventiontreatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the preventiontreatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the preventiontreatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the preventiontreatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substancesfibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the preventiontreatment and alleviation of pain and inflammationanti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the preventiontreatment and alleviation of migraines; Pharmaceutical preparations and substances for the treatment of epilepsyseizures and neurological and psychological diseases and disorders; Medicines and medicinal preparations for human purposesto support treatment of hemorrhoidschronic venous insufficiency and lymphedema; sanitary preparations for medical purposes; pharmaceutical preparations to support treatment of hemorrhoidschronic venous insufficiency and lymphedema; homeopathic pharmaceutics for use in support treatment of hemorrhoidschronic venous insufficiency and lymphedema and vitamin preparationsall in the form of tablets or powder or soft gelatin capsules or hard gelatin capsules; pharmaceutical preparations and substances for the prevention and treatment of disordersdiseasesconditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention and treatment of hypertension; Pharmaceutical preparations for the treatment of nauseaemesis; Acetaminophen sold as an analgesic for the relief of pain; Pharmaceutical productslipid and triglyceride reducing agents for use in the treatment of cardiovascular and heart disease; Diuretic preparations; pharmaceutical preparations and substances for the preventiontreatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the preventiontreatment and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the preventiontreatment and alleviation of epilepsy; pharmaceutical preparations and substances for the preventiontreatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the preventiontreatment and alleviation of cardio-pulmonary disordersdiseasesconditionsailments; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditionsailments of the circulatory system; pharmaceutical preparations and substances for the preventiontreatment and alleviation of hypertensionhigh blood pressureheart failure and ventricular dysfunction; pharmaceutical preparations and substances for the preventiontreatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the preventiontreatment and alleviation of central nervous system disordersdiseasesconditions and ailmentscentral nervous system movement disordersocular motility disordersspinal cord diseasesencephalitiscerebral palsyinsomniamood disordersbipolar disorderseizure disorders; pharmaceutical preparations and substancesfibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the respiratory system; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseasesauto immune motility diseasesimmunologic deficiency syndromesauto immune diseasesAcquired Immune Deficiency Syndrome (AIDS)hypersensitivityallergiestumors of the immunological organs; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the musculoskeletal systembone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the preventiontreatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the treatment of diabetes; pharmaceutical preparations and substances for the treatment of heart disease; pharmaceutical preparations and substances for the treatment of pain; pharmaceutical preparations and substances for the treatment of cardiovascular disease; pharmaceutical preparations and substances for the treatment of depression and social anxiety; pharmaceutical preparations and substances for the treatment of insomnia; pharmaceutical preparations and substances for the treatment of sleep disorders; pharmaceutical preparations and substances for the treatment of migraine and neurological disorders; Pharmaceutical preparations for the treatment of cancerneurological and dermatological disorders; pharmaceutical preparations for the treatment of myasthenia gravisdepressionmood/anxiety conditionssolar keratoses and cancer; antidepressants; tranquilizers; nasal spray preparations; Pharmaceutical preparations for the treatment of neuromuscular conditions; Pharmaceutical preparationsretinoidsfor the treatment of skin related diseasescancer and precancerous conditionsdisorders related to the modulation of apoptosis; vitamin supplement distributed by prescription only; pharmaceutical preparationsan oral glucose gel for the treatment of low blood sugar; pharmaceutical preparation for the treatment of headaches; pharmaceutical preparations;diazepam rectal gel; Methyltestosterone for use in the treatment of hormone deficiencies; medicated skin lotion for the relief of itch caused by insect biteseczemasunburn and poison ivy; Preparations and substances for the relief of anorectal discomfortinflammationirritation; hemorrhoidal suppositories; Pharmaceutical preparations for the treatment of irritable bowel syndrome; Drugs to treat opioid-induced constipation; Psychotropic preparations; Cough medicine in the nature of saline solutiona spray for nasal dryness due to allergiescold and flu; Dermotherapeutic preparation for use in the treatment of obesity; pharmaceutical preparations for the treatment of neurological disorders and movement disorders; antiobesity agent in the nature of a pharmaceutical preparation; and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the preventiontreatment and alleviation of anxietydepressiondepressive disorders and mental illness; tranquilizers and sedatives; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments
Classe 41
Providing on-line publications in the nature of newsletterspamphlets and bulletins in the field of health issues; newslettersarticlesinformational brochures and web-based tools
Classe 44
Providing a website featuring information and advice in the field of health issues
Publicações
Histórico de despachos e eventos da marca no USPTO.
81 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/05/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/05/2026
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
10/09/2025
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
25/07/2025
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
06/12/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/02/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
07/02/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/01/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/01/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/01/2023
IUAF
USE AMENDMENT FILED
01/01/2023
EISU
TEAS STATEMENT OF USE RECEIVED
01/01/2023
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
28/12/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
21/12/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
14/12/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/10/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/10/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/10/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/10/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/07/2022
EX5G
SOU EXTENSION 5 GRANTED
11/07/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/07/2022
EXT5
SOU EXTENSION 5 FILED
28/06/2022
EEXT
SOU TEAS EXTENSION RECEIVED
28/06/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
23/06/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
09/03/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/11/2021
EX4G
SOU EXTENSION 4 GRANTED
07/11/2021
EXT4
SOU EXTENSION 4 FILED
07/11/2021
EEXT
SOU TEAS EXTENSION RECEIVED
07/11/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
16/10/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
16/10/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
16/10/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/06/2021
EX3G
SOU EXTENSION 3 GRANTED
30/05/2021
EXT3
SOU EXTENSION 3 FILED
30/05/2021
EEXT
SOU TEAS EXTENSION RECEIVED
30/05/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/12/2020
EX2G
SOU EXTENSION 2 GRANTED
01/12/2020
EXT2
SOU EXTENSION 2 FILED
01/12/2020
EEXT
SOU TEAS EXTENSION RECEIVED
01/12/2020
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
25/11/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
19/05/2020
EX1G
SOU EXTENSION 1 GRANTED
15/05/2020
EXT1
SOU EXTENSION 1 FILED
15/05/2020
EEXT
SOU TEAS EXTENSION RECEIVED
15/05/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/05/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/05/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/05/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/05/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/05/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
31/12/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/11/2019
PUBO
PUBLISHED FOR OPPOSITION
05/11/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
16/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/09/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
28/09/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
28/09/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
28/09/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
28/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/09/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/09/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/09/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/03/2019
GNRT
NON-FINAL ACTION E-MAILED
08/03/2019
CNRT
NON-FINAL ACTION WRITTEN
08/03/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/02/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/02/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/02/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/02/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/02/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
15/08/2018
GNRT
NON-FINAL ACTION E-MAILED
15/08/2018
CNRT
NON-FINAL ACTION WRITTEN
15/08/2018
DOCK
ASSIGNED TO EXAMINER
09/08/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/07/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/07/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
27/04/2018
NWAP
NEW APPLICATION ENTERED
23/04/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BAUSCH HEALTH ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.